Rituximab is reported to be beneficial in some patients with FSGS [35,36], and we have found that treatment of mice with anti-CD20 reduced glomerular IgM deposition and complement activation in adriamycin nephropathy [10]. The gene discussed is CD40LG; the disease is focal segmental glomerulosclerosis.